The stock market cautiously advanced yet again on Friday, and the S&P 500 Index (SNPINDEX:^GSPC) even finished at a new record closing high. If only all of its components could be so lucky: shares of Regeneron Pharmaceuticals (NASDAQ:REGN), Oracle Corporation (NYSE:ORCL), and Darden Restaurants, (NYSE:DRI) ended as the benchmark index's three worst stocks, each declining by more than 3%. The S&P, for its part, added 3 points, or 0.2%, to end at 1,962.
Regeneron Pharmaceuticals, a biotech company that largely hinges on the success of its macular degeneration product Eylea, plunged 4.2% on Friday. BMO Capital issued a note to investors saying that around 10% of Eylea users are switching to other treatments -- a spooky stat that, if true, would justify some caution on behalf of Regeneron shareholders. Unfortunately for investors, BMO's note, while hardly authoritative, is putting the market on edge simply because it could potentially be onto something.
Wall Street analysts also played a role in Oracle's 4% slump today, though this negative sentiment was mostly earned as a result of the tech giant's underwhelming quarterly report. Both earnings per share, or EPS, and overall sales in the most recent quarter failed to meet estimates: EPS came in at $0.92 against a $0.95 projection, and revenue came in at $11.3 billion versus calls for $11.5 billion. Sales of new software licenses also failed to impress Oracle investors, as they remained flat year-over-year.
Finally, shares of Darden Restaurants, a restaurant operator that owns the Red Lobster, Olive Garden, and LongHorn Steakhouse brands, among others, lost 3.9% on Friday. Like Oracle, Darden Restaurants reported a bum quarter of sales and earnings, with Red Lobster and Olive Garden both losing revenue as earnings slipped 35% across the company. Its earnings per share projections for the current fiscal year also fell far below expectations, as the company forecast EPS between $2.22 and $2.30. Wall Street was hoping for EPS around $2.79. While investors can count their lucky stars that Darden's trying to dispose of its struggling Red Lobster franchise, the price tag probably took a hit today on the weak financial figures.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier, and more accurately, than anyone else. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, see The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.
The Motley Fool owns shares of Oracle. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.